<DOC>
	<DOC>NCT01007656</DOC>
	<brief_summary>- Study design is multiple-dose, open-label study - The purpose of this study is to evaluate the safety after twice daily GD Antrodia camphorata administration for 90 days in 30 healthy adult subjects. - Primary objective: The mean change from baseline in laboratory assessment after twice daily GD Antrodia camphorata administration at 90th day in 30 healthy adult subjects. - Secondary objective: The mean change from baseline in laboratory assessment after twice daily GD Antrodia camphorata administration at 10th, 20th, 30th, 45th and 60th day in 30 healthy adult subjects. - Safety Measurement: - including SGOT(AST), SGPT(ALT), albumin, glucose, creatinine, uric acid, cholesterol, TG, r-GT, alkaline phosphatase, total bilirubin, D-Bil, BUN, TP, GLO will be documented at 1st, 10th, 20th, 30th, 45th, 60th and 90th day. - vital signs (heart rate, blood pressure, and body temperature) will be documented at 1st, 10th, 20th, 30th, 45th, 60th and 90th day. - Subjects will be monitored throughout the confinement portion of the study.</brief_summary>
	<brief_title>A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects</brief_title>
	<detailed_description>- Study design is multiple-dose, open-label study - Antrodia camphorata has been proved to alleviate liver injury and fibrosis induced by chemical and reduces ALT and AST according to the literatures. - "GD Antrodia camphorata" will be marketed as dietary supplement. - The purpose of this study is to evaluate the safety after twice daily GD Antrodia camphorata administration for 90 days in 30 healthy adult subjects. - Primary objective: The mean change from baseline in laboratory assessment after twice daily GD Antrodia camphorata administration at 90th day in 30 healthy adult subjects. - Secondary objective: The mean change from baseline in laboratory assessment after twice daily GD Antrodia camphorata administration at 10th, 20th, 30th, 45th and 60th day in 30 healthy adult subjects. - Study design is multiple-dose, open-label study - The study site is Pingtung Christian Hospital Ruiguang Branch. - Safety Measurement: - including SGOT(AST), SGPT(ALT), albumin, glucose, creatinine, uric acid, cholesterol, TG, r-GT, alkaline phosphatase, total bilirubin, D-Bil, BUN, TP, GLO will be documented at 1st, 10th, 20th, 30th, 45th, 60th and 90th day. - vital signs (heart rate, blood pressure, and body temperature) will be documented at 1st, 10th, 20th, 30th, 45th, 60th and 90th day. - Subjects will be monitored throughout the confinement portion of the study.</detailed_description>
	<criteria>Healthy adult, aged between 20 to 40 years old Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, laboratory tests, chest Xray and electrocardiogram The normal range of the body mass index should between 18.5 and 24.9; body mass equals [weight(Kg)]/[height(m)]2 Normal laboratory determinations results (within normal range or considered not clinically significant by the investigator) including: SGOT (AST), SGPT (ALT), albumin, glucose, creatinine, uric acid, cholesterol, TG, Î³GT, alkaline phosphatase, total bilirubin, DBil, BUN, TP, GLO, HBsAg and AntiHCV. Normal hematology results (within normal range or considered not clinically significant by the investigator) including: hemoglobin, hematocrit, WBC count with differential, RBC count and platelet count. Normal urinalysis results (within normal range or considered not clinically significant by the investigator) including: glucose, protein, RBC, WBC, epith, casts and bacteria. Female subject who is using adequate contraception since last menstruation and no plan for conception during the study Female subject who is nonlactating Female subject who has negative pregnancy test (urine) within 14 days prior to the study Informed consent form signed A recent history of drug or alcohol abuse Medical history of allergic asthma or sensitivity to analogous product A clinically significant illness within the past 4 weeks. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoetic, neurological, pulmonary or gastrointestinal pathology within the past 4 weeks. Ongoing peptic ulcer and constipation. Planed vaccination during the time course of the study. Participation of any clinical investigation during the last 60 days. Regular use of any medication during the last 4 weeks. Single use of any medication during the last one week. Blood donation of more than 500 mL within the past 12 weeks. Individuals are judged by the investigators or coinvestigator to be undesirable as subjects.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>healthy adult subjects</keyword>
	<keyword>safety evaluation</keyword>
	<keyword>GD Antrodia camphorata</keyword>
</DOC>